Japanese Journal of Clinical Oncology Advance Access published online on November 22, 2005
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyi194
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
* To whom correspondence should be addressed. Background: Previously we reported that immunohistochemical examination of p53, bcl-2, glutathione S-transferase- Methods: The subjects were 55 unresectable gastric cancer patients treated with irinotecan (70 mg/m2, Days 1 and 15) and cisplatin (80 mg/m2, Day 1). Expression of p53, bcl-2, VEGF was examined immunohistochemically in biopsy samples. Results: The overall response rate and the median survival time were 55% (30/55) and 321 days, respectively. Thirty patients with intestinal-type adenocarcinoma survived longer than 25 patients with diffuse-type (median survival time: 446, 259 days, P = 0.013). The favorable phenotypes for chemoresponse were p53-negative, bcl-2-negative and VEGF-positive, which were in accordance with previous findings. The response rate was significantly correlated with the total number of these favorable phenotypes (P = 0.043). The 39 patients having 2 or 3 favorable phenotypes (p53-negative, bcl-2-negative and VEGF-positive) survived longer than the remaining 16 patients (median survival time: 444, 259 days, P = 0.021). In the Cox model, the number of the favorable phenotypes showed a tendency to correlate with survival after adjustment for potentially prognostic factors such as histological type or performance status (P = 0.070). Conclusions: Immunohistochemical examination of biological markers may be useful in predicting the clinical outcome of unresectable gastric cancer patients treated with irinotecan and cisplatin.
Received June 23, 2005
Accepted October 9, 2005
Original Article
Biological Markers as a Predictor for Response and Prognosis of Unresectable Gastric Cancer Patients Treated with Irinotecan and Cisplatin
Fumio Nagashima 1 *,
Narikazu Boku 1,
Atsushi Ohtsu 1,
Shigeaki Yoshida 1,
Takahiro Hasebe 2,
Atsushi Ochiai 2,
Yu Sakata 3,
Hiroshi Saito 4,
Yoshinori Miyata 5,
Ichinosuke Hyodo 6,
and
Masahiko Ando 7
2 Pathology Division, National Cancer Center Research Institute East, Kashiwa, Chiba, Japan
3 Department of Internal Medicine, Misawa City Hospital, Aomori, Japan
4 Department of Medicine, Yamagata Prefectural Central Hospital, Yamagata, Japan
5 Department of Medicine, Saku General Hospital, Nagano, Japan
6 Department of Internal Medicine, National Shikoku Cancer Center, Matsuyama, Japan
7 Health Service, Kyoto University, Kyoto, Japan
Fumio Nagashima, E-mail: fnagashi{at}saitama-med.ac.jp
Abstract 
(GST-), thymidylate synthase (TS) and vascular endothelial growth factor (VEGF) in biopsy samples was a useful method for predicting clinical outcome of gastric cancer patients treated with 5-fluorouracil and cisplatin. Here, we investigated if these biological markers can predict chemoresponse and survival of unresectable gastric cancer patients treated with irinotecan and cisplatin.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K R Fareed, P Kaye, I N Soomro, M Ilyas, S Martin, S L Parsons, and S Madhusudan Biomarkers of response to therapy in oesophago-gastric cancer Gut, January 1, 2009; 58(1): 127 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Boku, A. Ohtsu, F. Nagashima, K. Shirao, and W. Koizumi Relationship between Expression of Vascular Endothelial Growth Factor in Tumor Tissue from Gastric Cancers and Chemotherapy Effects: Comparison between S-1 alone and the Combination of S-1 plus CDDP Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym057v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Boku, A. Ohtsu, S. Yoshida, K. Shirao, Y. Shimada, I. Hyodo, H. Saito, Y. Miyata, and Gastrointestinal Oncology Study Group of Japan Cli Significance of Biological Markers for Predicting Prognosis and Selecting Chemotherapy Regimens of Advanced Gastric Cancer Patients between Continuous Infusion of 5-FU and a Combination of 5-FU and Cisplatin Jpn. J. Clin. Oncol., May 23, 2007; (2007) hym015v1. [Abstract] [Full Text] [PDF]
|
|